Seer Rejects Acquisition Proposals to Remain Independent
The Redwood City-based company will maintain its independence after a board committee concluded that recent buyout offers undervalued its business.
Updated on Oct. 29, 2026 in Business Strategy
Live Poll
Do you believe rejecting acquisition offers is generally the right move for public company shareholders?
The Special Committee of Seer's Board of Directors has unanimously rejected unsolicited acquisition proposals from the Radoff-JEC Group and CEO Omid Farokhzad. The committee determined that these offers did not accurately reflect the company's future prospects.
Why it matters
The board decided that maintaining independence is the superior path for the company as it works to meet rising demand for proteomics research. The rejection signals confidence in the firm's growth potential within the evolving field of AI-biology.
The Radoff-JEC Group submitted a proposal for $2.55 per share, while CEO Omid Farokhzad offered $2.45 per share for the company. Both bids included additional contingent value rights that the board found insufficient.
The players
Seer
This life sciences company is headquartered in Redwood City and specializes in proteomics research.
Radoff-JEC Group
This investment entity submitted an unsolicited proposal to acquire all outstanding shares of Seer.
Omid Farokhzad
He serves as the CEO of Seer and submitted a personal bid to take the company private.
The details
The Special Committee performed a three-month evaluation of strategic alternatives and potential interest from other counterparties alongside its legal and financial advisors. This thorough assessment led the board to conclude that the current proposals failed to adequately value the firm's long-term position.
Timeline
July 28, 2026: Radoff-JEC Group submitted its initial acquisition proposal.
July 29, 2026: CEO Omid Farokhzad submitted his separate acquisition proposal.
August 2026 - October 2026: The Special Committee conducted its formal review of strategic alternatives.
October 29, 2026: Seer announced the unanimous rejection of the acquisition proposals.
Market Landscape
The board's decision to reject buyout offers highlights a firm commitment to capturing the growing market for proteomics research. By remaining independent, the company positions itself to better capitalize on the emerging convergence of AI and biology.
The decision to remain independent means the company will continue its existing operations without a change in corporate ownership. Customers and partners can expect the firm to proceed with its current strategic roadmap regarding proteomics development.
The takeaway
The board's unanimous vote serves as a clear indication that leadership believes current market valuations underplay the long-term technological value of their platform. Shareholders and investors should monitor how the company executes its growth strategy in the coming quarters.
Further reading
Learn more about organizational decision-making in the Business Strategy section.
Source note: This article includes information reported by The Manila times.
Live Poll
Do you believe rejecting acquisition offers is generally the right move for public company shareholders?
